In a matter of immense pride for the state, a Malayali scientist has played a pivotal and central role in the development of an innovative, non-invasive medical technology that has recently achieved a major milestone in advanced knee treatment in the United States. The United States Food and Drug Administration (US FDA) has officially granted Investigational Device Exemption (IDE) approval for the human clinical trials of the cutting-edge SOLA-2 Alternating Magnetic Field (AMF) system. This revolutionary medical technology is developed by Solenic Medical Inc., a prominent medical device company headquartered in Dallas, Texas.
Dr. Bibin Prasad, a native of Haripad in Alappuzha district and a distinguished alumnus of the TKM College of Engineering, Kollam—where he successfully completed his MTech in the year 2011—is identified as one of the mastermind figures driving this innovative technology forward. He currently holds the prestigious position of Director of Research and Development (R&D) at Solenic Medical. In this key corporate role, he leads a team dedicated to designing advanced computational models and highly intricate scientific simulations that directly support medical device engineering and patient-specific surgical treatment planning.
Dr. Bibin initially commenced his foundational research work on the SOLA-2 system during his post-doctoral fellowship tenure at the prestigious University of Texas Southwestern Medical Center. During this research phase, he closely collaborated with Prof. Dr. Rajiv Chopra, the co-founder and Chief Technology Officer (CTO) of Solenic Medical. Since that initial phase, Dr. Bibin has remained a central and guiding force in advancing the technology from its early-stage laboratory research directly to the threshold of human-clinical evaluation. Highly commending his scientific contributions, Prof. Chopra noted that Bibin single-handedly led the complex development and rigorous validation of sophisticated electromagnetic and thermal simulation models. These models were absolutely critical for the device design, extensive preclinical trials, and human-safety regulatory assessments.
Prof. Chopra further emphasized that Dr. Bibin’s extensive research work has previously received high recognition from several reputed international scientific organisations and proved highly instrumental in generating the precise scientific and engineering evidence required to secure the FDA’s strict IDE clearance. The regulatory clearance successfully paves the definitive pathway for Solenic Medical to officially launch a pivotal, multicentre clinical trial across leading orthopaedic hospitals and premier academic medical centres throughout the United States. According to Dr. Bibin, formal patient enrolment for these clinical trials is strategically scheduled to begin in the second half of 2026.
The comprehensive clinical study will precisely evaluate the safety and clinical effectiveness of the SOLA-2 AMF system in treating highly infected artificial joint implants. If the upcoming human trials prove successful, this technology could proudly become one of the world’s very first non-invasive treatment modalities capable of completely curing infected prosthetic joints without ever removing the original implant from the patient’s body. Consequently, this medical breakthrough could potentially eliminate the absolute need for highly complex, risky, and expensive joint revision surgeries, thereby significantly improving long-term patient outcomes and recovery times.
Dr. Bibin Prasad originally hails from the Kuravuthara residential region in Karthikappally. He is the proud son of Rajendra Prasad, who formerly served as the general manager of the state-run Kerala State Drugs and Pharmaceuticals (KSDP) unit in Kalavoor; and Prof. Sheela, who is the former Head of the Department of Botany at TKMM College in Nangiarkulangara.
ലഘു വിവരണം അമേരിക്കയിലെ കാൽമുട്ട് ചികിത്സാ രംഗത്ത് നാഴികക്കല്ലായ പുതിയ ‘സോളാ-2’ (SOLA-2) സാങ്കേതികവിദ്യയുടെ ക്ലിനിക്കൽ ട്രയലിന് യുഎസ് എഫ്ഡിഎ അംഗീകാരം നൽകി. ഡാളസ് ആസ്ഥാനമായുള്ള സോലെനിക് മെഡിക്കൽ കമ്പനി വികസിപ്പിച്ച ഈ നോൺ-ഇൻവേസിവ് സാങ്കേതികവിദ്യയ്ക്ക് പിന്നിൽ ഹരിപ്പാട് സ്വദേശിയായ മലയാളി ശാസ്ത്രജ്ഞൻ ഡോ. ബിബിൻ പ്രസാദാണ്. കമ്പനിയുടെ ആർ ആൻഡ് ഡി ഡയറക്ടറായ ഇദ്ദേഹം വികസിപ്പിച്ച സിമുലേഷൻ മോഡലുകളാണ് എഫ്ഡിഎ അംഗീകാരത്തിന് വഴിതുറന്നത്. കൃത്രിമ സന്ധികളിലെ അണുബാധകൾ ശസ്ത്രക്രിയ കൂടാതെ മാറ്റാൻ ഈ സാങ്കേതികവിദ്യ സഹായിക്കും. ക്ലിനിക്കൽ ട്രയലുകൾ 2026 പകുതിയോടെ ആരംഭിക്കും.
(With inputs from TNIE)
For more details: Navamalayalam.com